Enoblituzumab, previously known as TJ-271 or MGA271, represents an novel monoclonal targeting CD33, a antigen found predominantly on cancer tissues. Such antibody operates as an two-pronged molecule, at once binding to https://www.targetmol.com/compound/enoblituzumab